Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs Tango Therapeutics Inc. — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $104.14 (market cap $20.78B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Direxion Daily Semiconductor Bull 3X Shares is far larger — about 5.5× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bull 3X Shares for 15 Days and Tango Therapeutics Inc. for 0 Days on average.
| SOXL | TNGX | |
|---|---|---|
Market Cap | $20.78B | $3.75B |
Volume | 78,745,280 | 9,619,106 |
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $32.90 |
52-Week Low | $30.81 | $7.50 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL (Direxion Daily Semiconductor Bull 3X ETF) trades at $127.57, down 0.65% on the day, with a bearish technical signal from moving averages. The ETF, which provides 3x leveraged exposure to semiconductor stocks, faces volatility amid mixed sentiment on chip sector prospects. Recent news highlights sector rallies and sharp declines, reflecting the amplified risk of leveraged products. Key support sits at $125, with resistance at $130.
Outlook is cautious due to leveraged structure and semiconductor cyclicality. Opportunities exist for tactical traders betting on AI-driven chip demand, but risks include sector volatility, regulatory tariffs, and erosion from daily rebalancing. Long-term holders face significant decay risk in volatile markets.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
